TheNewswire
30 Dec 2025, 14:20 UTC · 38w ago
Verdict
Headline takes no side. We score LEXX +0.80 across five claims — strongly bullish.
+0.80strongly bullish
More positive than 85% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
DHT-semaglutide showed a proportionally lower reduction in lean mass compared to fat mass than the Rybelsus control arm.
So whatPreserving lean muscle mass while losing fat is a highly desirable clinical outcome for GLP-1 drugs, providing a competitive advantage over existing treatments.
More positive than 92% of claims this week
The DHT-CBD arm achieved meaningful reductions in systolic and diastolic blood pressure, even in non-hypertensive participants.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 85% of claims this week
DHT-semaglutide participants reported higher improvements in physical and mental health (SF-36 survey) than those in the Rybelsus arm.
More positive than 77% of claims this week
DHT arms reached rough parity with Rybelsus in secondary efficacy parameters including fasting glucose, cholesterol, and LDL cholesterol.
More positive than 50% of claims this week
Initial LCMS assay failed to quantify plasma semaglutide concentrations for DHT arms, though a separate ELISA test did detect measurable levels.
More negative than 71% of claims this week
Which stocks this story touches
More positive than 85% of ticker scores this week
The company reported positive Phase 1b clinical data showing good safety, tolerability, and potential benefits of its DehydraTECH platform.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−62.0%
Price is moving against the score
$3.19 vs $8.40 close before publication (Dec 29) · not market-adjusted
LEXX chart →
